Reviewnpj drug discovery2026
Mechanistic and therapeutic insights into class A GPCR dimers in neuropsychiatric disorders.
Review in npj drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Class A G protein-coupled receptors (GPCRs) constitute the majority of the clinical GPCR targets and are implicated in a wide range of neuropsychiatric disorders. Dimerization of class A GPCRs often introduces unique modes of allosteric modulation, leading to the reprogramming of the downstream signaling relative to individual protomers. In this review, we highlight the experimental evidence and pharmacological properties of class A GPCR dimers involved in mental disorders. We further elucidate the molecular basis of dimer assembly and activation through a comprehensive structural analysis of currently available class A GPCR dimers. Current strategies and therapeutic potential of dimer-specific targeting are also discussed. Together, these insights provide a framework for understanding class A GPCR dimer function and pave the way for the development of dimer-informed therapeutics.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.